Top-Rated StocksTop-RatedNASDAQ:RAPP Rapport Therapeutics (RAPP) Stock Price, News & Analysis $31.30 +0.15 (+0.47%) As of 02:36 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Rapport Therapeutics Stock (NASDAQ:RAPP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rapport Therapeutics alerts:Sign Up Key Stats Today's Range$30.46▼$31.3550-Day Range$31.15▼$52.5052-Week Range$23.75▼$52.93Volume184,054 shsAverage Volume356,267 shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice Target$66.11Consensus RatingBuy Company Overview Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system. Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy. The company is also advancing additional discovery and preclinical programs intended to address other nervous system conditions, with a focus on developing selective treatments that may offer improved efficacy and tolerability compared with less targeted approaches. Rapport Therapeutics was established to apply receptor-associated protein biology to drug discovery and is headquartered in Boston, Massachusetts. Its development efforts are directed primarily toward neurological and psychiatric diseases affecting patients in global markets. Information about the company’s leadership and broader commercial operations is limited because Rapport remains focused on clinical development rather than marketing approved products.AI Generated. May Contain Errors. Read More Rapport Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreRAPP MarketRank™: Rapport Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 424th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingRapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRapport Therapeutics has a consensus price target of $66.11, representing about 112.2% upside from its current price of $31.16.Amount of Analyst CoverageRapport Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rapport Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rapport Therapeutics are expected to decrease in the coming year, from ($4.09) to ($4.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rapport Therapeutics is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rapport Therapeutics is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRapport Therapeutics has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rapport Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.35% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 7.91.Change versus previous monthShort interest in Rapport Therapeutics has recently increased by 0.64%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRapport Therapeutics does not currently pay a dividend.Dividend GrowthRapport Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.49 News SentimentRapport Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Rapport Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for RAPP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rapport Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,277,081.00 in company stock.Percentage Held by Insiders12.48% of the stock of Rapport Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsRapport Therapeutics has minimal institutional ownership at this time.Read more about Rapport Therapeutics' insider trading history. Receive RAPP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RAPP Stock News HeadlinesGuggenheim Upgrades Rapport Therapeutics (NASDAQ:RAPP) to "Strong-Buy"October 7 at 7:37 AM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Stock: Insider Cheryl Gault Sells 10,000 SharesOctober 3, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 7 at 1:00 AM | Stansberry Research (Ad)Rapport Therapeutics (NASDAQ:RAPP) COO Sells $331,900.00 in StockOctober 2, 2026 | insidertrades.comRapport Therapeutics, Inc. (NASDAQ:RAPP) Stock Now Rated "Buy" by Wall Street BrokeragesOctober 1, 2026 | americanbankingnews.comShow Me The Money: Rapport Stock Up Over 400% In 16 Months; Bipolar Mania Data NextSeptember 26, 2026 | rttnews.comRapport Therapeutics (NASDAQ:RAPP) CEO Sells $86,565.70 in StockSeptember 25, 2026 | insidertrades.comInsider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $374,458.10 in StockSeptember 10, 2026 | insidertrades.comSee More Headlines RAPP Stock Analysis - Frequently Asked Questions How have RAPP shares performed this year? Rapport Therapeutics' stock was trading at $30.34 at the beginning of the year. Since then, RAPP shares have increased by 2.7% and is now trading at $31.16. How were Rapport Therapeutics' earnings last quarter? Rapport Therapeutics, Inc. (NASDAQ:RAPP) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by $0.07. When did Rapport Therapeutics IPO? Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at $17.00 per share. How do I buy shares of Rapport Therapeutics? Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rapport Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Navios Maritime Partners (NMM). Company Calendar Last Earnings8/05/2026Today10/07/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 5 days ago, RAPP's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RAPP Previous SymbolNASDAQ:RAPP CIK2012593 Webwww.rapportrx.com Phone(857) 321-8020FaxN/AEmployees84Year Founded2022Price Target and Rating Average Price Target for Rapport Therapeutics$66.11 High Price Target$80.00 Low Price Target$46.00 Potential Upside/Downside+112.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.48 million Net MarginsN/A Pretax Margin-685.80% Return on Equity-29.02% Return on Assets-27.37% Debt Debt-to-Equity RatioN/A Current Ratio15.72 Quick Ratio15.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book3.06Miscellaneous Outstanding Shares47,980,000Free Float41,990,000Market Cap$1.50 billion OptionableN/A Beta1.22 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:RAPP) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
